What is HC Wainwright’s Forecast for SGMO FY2028 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Investment analysts at HC Wainwright boosted their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of $0.64 for the year, up from their prior estimate of $0.63. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.51) per share.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same quarter last year, the company posted ($0.34) EPS.

Other equities analysts have also recently issued reports about the stock. StockNews.com raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Barclays increased their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday.

Sangamo Therapeutics Stock Down 4.7 %

SGMO opened at $2.05 on Friday. The company has a market capitalization of $427.67 million, a PE ratio of -2.73 and a beta of 1.10. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The firm has a 50-day simple moving average of $1.33 and a two-hundred day simple moving average of $0.86.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System raised its position in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Sangamo Therapeutics in the second quarter valued at about $67,000. Meritage Portfolio Management raised its position in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Sangamo Therapeutics in the second quarter valued at approximately $89,000. Finally, XTX Topco Ltd lifted its position in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares in the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.